Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Allantoic Split Inactivated Seasonal Influenza Vaccine (VSI)
NCT03028116Phase 1Completed
- Sponsor
- Research Institute for Biological Safety Problems
- Start
- May 2016
- Primary completion
- Jun 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ARCT-2138 in influenza (2 arms), sponsored by Research Institute for Biological Safety Problems. Primary endpoints: Percentage of Participants With Solicited Local and Systemic Adverse Events at 2 hours, Percentage of Participants Reporting One or More Treatment-emergent Adverse Events at 7 days and 2 more. Started May 2016; status: completed.
02
Drugs
ARCT-2138
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03028116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03028116.